Study about glucose and lipid metabolism of DPP-4 inhibitor versus ipragliflozin in inadequately controlled type 2 diabetes

Trial Profile

Study about glucose and lipid metabolism of DPP-4 inhibitor versus ipragliflozin in inadequately controlled type 2 diabetes

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 May 2017

At a glance

  • Drugs Ipragliflozin (Primary) ; CD26 antigen inhibitors
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LEVELUP trial
  • Most Recent Events

    • 11 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 08 Apr 2015 Status changed from not yet recruiting to recruiting as per University Hospital Medical Information Network - Japan.
    • 17 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top